STAT3 and neoplasm: By blocking key transcriptional programs responsible for immune cell reprogramming, STAT3 inhibition can suppress or reverse the pro-tumorgenic phenotype and can potentially restore immune surveillance capacity, thereby complementing existing tumor-targeted therapies and potentially enhancing the responsiveness to checkpoint blockade.